A study published in the Journal of Immunologyreveals significant differences in how four seasonal influenza vaccines activate critical immune cells, with effectiveness varying substantially by age and vaccine type.
The findings come during a severe 2024-2025 flu season that caused 47 million illnesses, 610,000 hospitalizations, and 27,000 deaths in the United States alone. While all vaccines generated similar antibody levels, their ability to activate cellular immunity—a crucial predictor of durable protection—differed markedly, providing new insights for age-specific vaccine recommendations.
Study Design and Vaccine Comparison
Researchers compared immune responses generated by four FDA-approved influenza vaccines:
- Fluzone High-Dose: Contains four times the antigen of standard-dose vaccines
- Fluzone Standard-Dose: Traditional egg-based vaccine
- Flucelvax: Mammalian cell culture-based vaccine
- Fluad: Adjuvanted vaccine containing MF59 to enhance immune response
The study enrolled participants across two age groups: younger adults (28-60 years) and older adults (65-85 years), analyzing both antibody production and cellular immunity markers.
Key Findings by Age Group
Older Adults (65-85 years):
- Fluzone High-Dose elicited the strongest coordinated B-cell and T-cell responses
- Enhanced early activation of circulating T-follicular helper cells and antibody-secreting cells
- Superior induction of immune memory cells critical for long-term protection
Younger Adults (28-60 years):
- Flucelvax outperformed standard Fluzone in cellular immunity measures
- Better induction of multifunctional cytokine-secreting CD4⁺ T cells coordinating complex immune responses
- More robust memory B-cell development compared to egg-based vaccines
Clinical Implications and Vaccine Selection
“While antibody levels were similar across vaccines, the quality of immune activation differed significantly,” stated the lead researcher.
“This suggests that matching vaccine type to patient age could optimize protection—particularly important for older adults who often have weakened immune responses.” The findings support current recommendations for high-dose or adjuvanted vaccines in older populations while suggesting cell-based vaccines may offer advantages for younger adults.
Research Methodology and Immune Monitoring
The study employed advanced flow cytometry to track multiple immune parameters beyond standard antibody measurements. Researchers specifically monitored:
- T-follicular helper cell activation: Critical for B-cell help and antibody maturation
- Memory B-cell formation: Essential for long-term immunity
- Polyfunctional T-cell responses: Indicators of robust, coordinated immunity
This comprehensive approach provided insights into vaccine performance that traditional antibody-based measures might miss.
Public Health Recommendations and Future Directions
With influenza remaining a major cause of morbidity and mortality, particularly among older adults, these findings strengthen the evidence base for targeted vaccine selection.
The research team emphasizes the importance of considering cellular immunity in vaccine effectiveness evaluations and recommends further studies to confirm whether superior immune cell activation translates to improved real-world protection against infection and severe outcomes.
Related topics:
